canakinumab Injection

Brand(s)
Ilaris
Category(s)
prescription
SPL Type(s)
Human Prescription
Master SPL
Novartis Pharmaceuticals Corporation (2014-10-16)
Oldest Current Product
2009-06-18
License(s)
BLA
RxNORM
INJECTION\CANAKINUMAB
SPL Active
SUBCUTANEOUS\INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION\CANAKINUMAB
SPL Moiety
SUBCUTANEOUS\INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION\CANAKINUMAB

product(s) by strength(s)

canakinumab 180 mg injection

original product(s)(s)

#idbrandcategorylabelerfirst marketedactive ingredient(s)routedose formapplicationspl
1000780582IlarisBLANovartis Pharmaceuticals Corporation2009-06-18CANAKINUMABSUBCUTANEOUSINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION1253197d271f3b-e4f9-4d80-8dcf-28d49123f80e

application(s)

#idtitleapprovedtradenamesfda division
1125319canakinumab Application2009-06-17IlarisCDER

spl(s)

#idtitlecategorytypelabelerlast updateversionproduct(s)
17d271f3b-e4f9-4d80-8dcf-28d49123f80e (view SPL)These highlights do not include all the information needed to use ILARIS safely and effectively. See full prescribing information for ILARIS. ILARIS (canakinumab) injection for subcutaneous use Initial U.S. Approval: 2009prescriptionHuman PrescriptionNovartis Pharmaceuticals Corporation2014-10-1614000780582

Data from: FDAOB, FDAPB, LOINC, MTHSPL, NDFRT, NCIT, RxNORM, UNII